Oncol-话题@MedSci

#Oncol#

2384篇内容 | 2484人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1866615, encodeId=39e9186661584, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：III期CROWN研究事后分析表明Lorlatinib (劳拉替尼)一线治疗较克唑替尼改善ALK阳性晚期NSCLC有或无脑转移患者的PFS, objectType=article, longId=727788, objectId=2cfae27788c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cfae27788c8, replyNumber=0, likeNumber=103, createdTime=2023-02-20, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cfae27788c8, moduleTitle=J Clin Oncol：III期CROWN研究事后分析表明Lorlatinib (劳拉替尼)一线治疗较克唑替尼改善ALK阳性晚期NSCLC有或无脑转移患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cfae27788c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866299, encodeId=b9eb186629922, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：阿帕替尼联合卡瑞利珠单抗在既往治疗过的晚期胆管癌患者中的疗效和安全性, objectType=article, longId=218851, objectId=26532188515c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26532188515c, replyNumber=0, likeNumber=73, createdTime=2022-08-16, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26532188515c, moduleTitle=Front Oncol：阿帕替尼联合卡瑞利珠单抗在既往治疗过的晚期胆管癌患者中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26532188515c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866343, encodeId=8f51186634338, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：非小细胞肺癌脑转移的局部与全身治疗作为首次治疗的生存比较, objectType=article, longId=220149, objectId=2be822014982, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2be822014982, replyNumber=0, likeNumber=63, createdTime=2022-04-23, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2be822014982, moduleTitle=Front Oncol：非小细胞肺癌脑转移的局部与全身治疗作为首次治疗的生存比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2be822014982)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866295, encodeId=eac0186629548, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：诱导化疗联合调强放疗(IMRT)治疗同时性转移鼻咽癌患者的疗效, objectType=article, longId=218758, objectId=6628218e582f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6628218e582f, replyNumber=0, likeNumber=62, createdTime=2022-06-24, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6628218e582f, moduleTitle=Front Oncol：诱导化疗联合调强放疗(IMRT)治疗同时性转移鼻咽癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6628218e582f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866262, encodeId=0fd518662626f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：II期单臂研究评估阿帕替尼联合口服依托泊苷治疗经治转移性乳腺癌的疗效, objectType=article, longId=218039, objectId=80b0218039e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80b0218039e3, replyNumber=0, likeNumber=74, createdTime=2021-12-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80b0218039e3, moduleTitle=Front Oncol：II期单臂研究评估阿帕替尼联合口服依托泊苷治疗经治转移性乳腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80b0218039e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866568, encodeId=2b931866568ea, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：低剂量白蛋白紫杉醇联合PD-1抑制剂（替雷利珠单抗）治疗老年晚期非小细胞肺癌（NSCLC）患者的疗效, objectType=article, longId=301507, objectId=2ec730150e2b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ec730150e2b, replyNumber=0, likeNumber=64, createdTime=2022-04-25, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ec730150e2b, moduleTitle=Front Oncol：低剂量白蛋白紫杉醇联合PD-1抑制剂（替雷利珠单抗）治疗老年晚期非小细胞肺癌（NSCLC）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ec730150e2b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866487, encodeId=4ac2186648e1b, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：围手术期化疗与胃肝样腺癌(HAS)患者预后的关系, objectType=article, longId=295129, objectId=43332951291a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43332951291a, replyNumber=0, likeNumber=60, createdTime=2022-04-11, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43332951291a, moduleTitle=Front Oncol：围手术期化疗与胃肝样腺癌(HAS)患者预后的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43332951291a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866359, encodeId=6d8b18663595d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：腹腔镜与开放式根治性子宫切除术治疗2018版FIGO IA2-IIA2期宫颈癌患者的生存结果比较:倾向性评分加权分析, objectType=article, longId=220525, objectId=9ffb22052592, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ffb22052592, replyNumber=0, likeNumber=74, createdTime=2022-06-01, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ffb22052592, moduleTitle=Front Oncol：腹腔镜与开放式根治性子宫切除术治疗2018版FIGO IA2-IIA2期宫颈癌患者的生存结果比较:倾向性评分加权分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ffb22052592)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866539, encodeId=fda5186653900, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ther Adv Med Oncol：北京协和医院团队真实世界探索HER2改变的晚期NSCLC患者更佳一线治疗方案, objectType=article, longId=300517, objectId=5c7c30051ed6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c7c30051ed6, replyNumber=0, likeNumber=57, createdTime=2022-06-05, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c7c30051ed6, moduleTitle=Ther Adv Med Oncol：北京协和医院团队真实世界探索HER2改变的晚期NSCLC患者更佳一线治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c7c30051ed6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866334, encodeId=64a9186633411, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：7项RCT荟萃分析显示，曲珠单抗可降低三分之一早期HER2乳腺癌患者的复发率和死亡率！, objectType=article, longId=219902, objectId=756d219902ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=756d219902ba, replyNumber=0, likeNumber=77, createdTime=2022-10-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=756d219902ba, moduleTitle=Lancet Oncol：7项RCT荟萃分析显示，曲珠单抗可降低三分之一早期HER2乳腺癌患者的复发率和死亡率！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=756d219902ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866219, encodeId=adf818662198d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Thorac Oncol：CNS渗透性TKI单药vs TKI+放疗治疗EGFR/ALK阳性NSCLC脑转移患者的疗效 , objectType=article, longId=217043, objectId=644421e04318, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=644421e04318, replyNumber=0, likeNumber=54, createdTime=2022-07-11, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=644421e04318, moduleTitle=J Thorac Oncol：CNS渗透性TKI单药vs TKI+放疗治疗EGFR/ALK阳性NSCLC脑转移患者的疗效 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=644421e04318)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866292, encodeId=2c0c1866292dc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：胃MALT淋巴瘤的长期生存结局:来自韩国的多中心研究结果, objectType=article, longId=218721, objectId=43ac218e212a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43ac218e212a, replyNumber=0, likeNumber=57, createdTime=2021-11-21, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43ac218e212a, moduleTitle=Front Oncol：胃MALT淋巴瘤的长期生存结局:来自韩国的多中心研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43ac218e212a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866207, encodeId=9a76186620e4b, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：腹股沟放疗可替代前哨淋巴结微转移的外阴癌患者的淋巴结清扫术, objectType=article, longId=216471, objectId=35f92164e1f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35f92164e1f5, replyNumber=0, likeNumber=71, createdTime=2021-11-10, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35f92164e1f5, moduleTitle=J Clin Oncol：腹股沟放疗可替代前哨淋巴结微转移的外阴癌患者的淋巴结清扫术, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35f92164e1f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866583, encodeId=47151866583f6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：采用ADC药物Anetumab ravtansine治疗恶性胸膜间皮瘤的疗效和安全性, objectType=article, longId=723522, objectId=d134e23522a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d134e23522a2, replyNumber=0, likeNumber=78, createdTime=2022-04-17, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d134e23522a2, moduleTitle=Lancet Oncol：采用ADC药物Anetumab ravtansine治疗恶性胸膜间皮瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d134e23522a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866530, encodeId=7c451866530ce, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ther Adv Med Oncol：依维莫司联合顺铂治疗晚期肺外神经内分泌癌(EP-NEC)的疗效和安全性, objectType=article, longId=300077, objectId=1a413000e765, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a413000e765, replyNumber=0, likeNumber=73, createdTime=2022-07-22, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a413000e765, moduleTitle=Ther Adv Med Oncol：依维莫司联合顺铂治疗晚期肺外神经内分泌癌(EP-NEC)的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a413000e765)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866152, encodeId=9c3518661523e, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Hematol Oncol：PD-1单抗---杰诺单抗注射液(geptanolimab）对外周T细胞淋巴瘤(PTCL) 的疗效与安全性, objectType=article, longId=214110, objectId=d47e2141105c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d47e2141105c, replyNumber=0, likeNumber=85, createdTime=2022-02-06, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d47e2141105c, moduleTitle=J Hematol Oncol：PD-1单抗---杰诺单抗注射液(geptanolimab）对外周T细胞淋巴瘤(PTCL) 的疗效与安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d47e2141105c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866594, encodeId=df041866594f5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：纳索普利单抗治疗造血干细胞移植相关血栓性微血管病的效果和安全性, objectType=article, longId=724762, objectId=4a8ee24762f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a8ee24762f1, replyNumber=0, likeNumber=88, createdTime=2022-12-03, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a8ee24762f1, moduleTitle=J Clin Oncol：纳索普利单抗治疗造血干细胞移植相关血栓性微血管病的效果和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a8ee24762f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866265, encodeId=da2218662658c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：转移性结直肠癌（mCRC）患者使用标准的一线治疗时，KRAS G12C突变与其他亚型对于治疗的应答以及预后的比较, objectType=article, longId=218078, objectId=d5152180e802, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5152180e802, replyNumber=0, likeNumber=79, createdTime=2022-02-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5152180e802, moduleTitle=Front Oncol：转移性结直肠癌（mCRC）患者使用标准的一线治疗时，KRAS G12C突变与其他亚型对于治疗的应答以及预后的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5152180e802)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866346, encodeId=6e6b1866346b5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：包括抗血管抑制剂，PD-1抑制剂以及肝动脉灌注化疗（HAIC）的三联疗法治疗初始不可切除肝细胞癌时手术转化能力的回顾性评估, objectType=article, longId=220296, objectId=ddf8220296a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddf8220296a1, replyNumber=0, likeNumber=82, createdTime=2022-06-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddf8220296a1, moduleTitle=Front Oncol：包括抗血管抑制剂，PD-1抑制剂以及肝动脉灌注化疗（HAIC）的三联疗法治疗初始不可切除肝细胞癌时手术转化能力的回顾性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddf8220296a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866171, encodeId=fc2818661e1df, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：Acalabrutinib和依鲁替尼用于CLL的长期疗效PK！, objectType=article, longId=214991, objectId=9fdb214991ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fdb214991ba, replyNumber=0, likeNumber=73, createdTime=2021-12-15, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fdb214991ba, moduleTitle=J Clin Oncol：Acalabrutinib和依鲁替尼用于CLL的长期疗效PK！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fdb214991ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Oncol

2020-05-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：III期CROWN研究事后分析表明Lorlatinib (劳拉替尼)一线治疗较克唑替尼改善ALK阳性晚期NSCLC有或无脑转移患者的PFS

2023-02-20

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：阿帕替尼联合卡瑞利珠单抗在既往治疗过的晚期胆管癌患者中的疗效和安全性

2022-08-16

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：非小细胞肺癌脑转移的局部与全身治疗作为首次治疗的生存比较

2022-04-23

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：诱导化疗联合调强放疗(IMRT)治疗同时性转移鼻咽癌患者的疗效

2022-06-24

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：II期单臂研究评估阿帕替尼联合口服依托泊苷治疗经治转移性乳腺癌的疗效

2021-12-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：低剂量白蛋白紫杉醇联合PD-1抑制剂（替雷利珠单抗）治疗老年晚期非小细胞肺癌（NSCLC）患者的疗效

2022-04-25

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：围手术期化疗与胃肝样腺癌(HAS)患者预后的关系

2022-04-11

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：腹腔镜与开放式根治性子宫切除术治疗2018版FIGO IA2-IIA2期宫颈癌患者的生存结果比较:倾向性评分加权分析

2022-06-01

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ther Adv Med Oncol：北京协和医院团队真实世界探索HER2改变的晚期NSCLC患者更佳一线治疗方案

2022-06-05

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：7项RCT荟萃分析显示，曲珠单抗可降低三分之一早期HER2乳腺癌患者的复发率和死亡率！

2022-10-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Thorac Oncol：CNS渗透性TKI单药vs TKI+放疗治疗EGFR/ALK阳性NSCLC脑转移患者的疗效

2022-07-11

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：胃MALT淋巴瘤的长期生存结局:来自韩国的多中心研究结果

2021-11-21

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：腹股沟放疗可替代前哨淋巴结微转移的外阴癌患者的淋巴结清扫术

2021-11-10

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：采用ADC药物Anetumab ravtansine治疗恶性胸膜间皮瘤的疗效和安全性

2022-04-17

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ther Adv Med Oncol：依维莫司联合顺铂治疗晚期肺外神经内分泌癌(EP-NEC)的疗效和安全性

2022-07-22

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Hematol Oncol：PD-1单抗---杰诺单抗注射液(geptanolimab）对外周T细胞淋巴瘤(PTCL) 的疗效与安全性

2022-02-06

智智灵药 (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：纳索普利单抗治疗造血干细胞移植相关血栓性微血管病的效果和安全性

2022-12-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：转移性结直肠癌（mCRC）患者使用标准的一线治疗时，KRAS G12C突变与其他亚型对于治疗的应答以及预后的比较

2022-02-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：包括抗血管抑制剂，PD-1抑制剂以及肝动脉灌注化疗（HAIC）的三联疗法治疗初始不可切除肝细胞癌时手术转化能力的回顾性评估

2022-06-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：Acalabrutinib和依鲁替尼用于CLL的长期疗效PK！

2021-12-15

科室
- - 订阅+
  - 更多科室
工具
服务